Enoxaparin Injectable Solution — Competitive Intelligence Brief

Enoxaparin Injectable Solution (Enoxaparin Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Coagulation factors Xa and IIa Cardiovascular Small molecule

Target snapshot

Enoxaparin Injectable Solution (Enoxaparin Injectable Solution) — Medical University of Vienna. Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Enoxaparin Injectable Solution TARGET	Enoxaparin Injectable Solution	Medical University of Vienna	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Coagulation factors Xa and IIa
Enoxaparin (High-dose Group)	Enoxaparin (High-dose Group)	Peking Union Medical College Hospital	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (enhancer); Coagulation factors Xa and IIa (indirect targets)
dalteparin injection	dalteparin injection	University of Rochester	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (Factor Xa and Factor IIa)
Usual dose adjustment of enoxaparin	Usual dose adjustment of enoxaparin	Assistance Publique - Hôpitaux de Paris	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III)
normal injection of Enoxaparine	normal injection of Enoxaparine	French Cardiology Society	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III enhancement)
dose adaptation of Enoxaparin	dose adaptation of Enoxaparin	French Cardiology Society	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III enhancement)
Hepalean Heparin	Hepalean Heparin	McMaster University	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Factors Xa and IIa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
2. University of Melbourne · 3 drugs in this class
3. French Cardiology Society · 2 drugs in this class
4. Ottawa Hospital Research Institute · 2 drugs in this class
5. McMaster University · 2 drugs in this class
6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
7. GlaxoSmithKline · 1 drug in this class
8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
10. Helsinki University Central Hospital · 1 drug in this class